目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T22303 | Bcr-Abl Src c-Kit | ||
Dasatinib hydrochloride (BMS-354825 HCl) (BMS-354825) hydrochloride 是一种具有口服活性的,ATP 竞争性的,双重 Src/Bcr-Abl 抑制剂,具有有效的抗肿瘤活性。对 Src 和 Bcr-Abl 的 Ki 值分别为 16 pM 和 30 pM。Dasatinib hydrochloride hydrochloride 抑制 Bcr-Abl 和 Src 的IC50 分别为 <1.0 nM 和 0.5 nM。Dasatinib hydrochloride hydrochloride 还诱导凋亡 (apoptosis) 和自噬 (autophagy)。 | |||
T23182 | Bcr-Abl | ||
PPY A 是 T315l 突变体和野生型 Abl 激酶的有效抑制剂(IC50 分别为 9 和 20 nM)。PPY A 还能抑制 Bcr-Abl T315l 突变体或野生型 Bcr-Abl 基因转化细胞的生长。 | |||
T80676 | Bcr-Abl | ||
AKE-72 是一种 Pan-BCR-ABL 抑制剂,具有抗白血病活性,抑制表达天然 BCR-ABL 或其 T315I 突变体的 Ba/F3 细胞的增殖,可用于研究白血病。 | |||
T28374 | Bcr-Abl | ||
PF-06651481-00 (Bosutinib Isomer I) 是 Bosutinib 类似物和 Bcr-Abl 抑制剂。 | |||
T26625 | Bcr-Abl | ||
AN-019 (NRC-019) 是一种 Bcr-Abl 激酶抑制剂, 具有抗肿瘤活性,可用于研究慢性粒细胞白血病(CML)和乳腺癌。 | |||
T63875 | Bcr-Abl Src | ||
Bosutinib hydrate (SKI-606 hydrate) 是一种可口服的高效 BCR-ABL 和 Src 酪氨酸激酶的双重激酶抑制剂,可用于研究费城染色体阳性慢性粒细胞白血病。 | |||
T64338 | Aurora Kinase | ||
AKI603 是一种极光激酶 A 抑制剂,IC50值为 12.3 nM。它对白血病细胞具有很强的抗增殖活性,可用于克服白血病中 BCR-ABL-T315I 耐药性突变。 | |||
T60081 | Others | ||
BV02 是 14-3-3 蛋白-蛋白相互作用的抑制剂,可用于治疗慢性粒细胞白血病的研究。 BV02 破坏表达 IM 抗性 T315I 突变和 IM 敏感的野生型 Bcr-Abl 的造血细胞。 | |||
T2328 | Bcr-Abl | ||
Radotinib (IY-5511) 有时被称为 IY5511,是一种用于治疗不同类型 Y 的药物,最显着的是费城染色体阳性 (Ph+) 慢性粒细胞白血病 (CML) 对其他酪氨酸激酶 Bcr-Abl 的耐药性或不耐受性抑制剂 | |||
T37600 | Others | ||
Dasatinib N-oxide 是 Dasatinib 的一种次要代谢物。Dasatinib 是口服有效的 Src/Bcr-Abl 抑制剂。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-04396 | C-ABL/ABL1 Protein, Human, Recombinant (GST) | Human | Baculovirus Insect Cells | ||
c-Abl belongs to the class of tyrosine kinases and is the prototype of a subfamily which includes two members, c-Abl and Arg (Abl-related gene). Both proteins are localized at the cell membrane, actin cytoskeleton and cytosol, and c-Abl is present in the nucleus as well. c-Abl is a non-receptor tyrosine kinase that participates in multiple signaling pathways linking the cell surface, cytoskeleton, and the nucleus. Recent in vitro studies have also linked c-Abl to amyloid-beta-induced toxicity and tau phosphorylation. c-Abl has been implicated in many cellular processes including differentiation, division, adhesion, death, and stress response. c-Abl is a latent tyrosine kinase that becomes activated in response to numerous extra- and intra-cellular stimuli. The c-Abl protein is a ubiquitously expressed nonreceptor tyrosine kinase involved in the development and function of many mammalian organ systems, including the immune system and bone. It regulates the cellular response to TAM through functional interaction with the estrogen receptor, which suggests c-Abl as a therapeutic target and a prognostic tumor marker for breast cancer. c-Abl also plays a key role in signaling chemokine-induced T-cell migration. In addition, c-Abl contains NLSs (nuclear localization signals) and DNA-binding sequences important for nuclear functions. c-Abl has become an important therapeutic target in human chronic myeloid leukaemia.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPY-00758 | Aminopeptidase N/CD13 Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells | ||
Aminopeptidase N/CD13 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 104 kDa and the accession number is P97449.
|
|||||
TMPY-00665 | Aminopeptidase N/CD13 Protein, Human, Recombinant (I603M, His) | Human | HEK293 Cells | ||
Aminopeptidase N/CD13 Protein, Human, Recombinant (I603M, His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 104.2 kDa and the accession number is A0A024RC61.
|